Achieving a pathologic complete response (pCR) after NAC significantly improves survival, particularly in patients with human epidermal growth factor receptor-2 (HER2) positive and triple negative breast cancer (TNBC) [1]. Here, ERBB2 is linked to triple-negative breast carcinoma.